Market Place
Sourcing Support
Merz wins $185m bid for bankrupt Acorda assets and increases US workforce by 50%
11 Jul 2024 //
PHARMACEUTICAL-TECHNOLOGY
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
10 Jul 2024 //
BUSINESSWIRE
Acorda files for bankruptcy, inks $185M asset deal to Merz
03 Apr 2024 //
FIERCE PHARMA
Acorda and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
01 Apr 2024 //
BUSINESSWIRE
Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda
12 Jan 2024 //
FIERCE PHARMA
NICE opts to reject Acorda’s MS drug Fampyra
22 Jun 2022 //
PHARMATIMES
Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
09 Mar 2022 //
BUSINESSWIRE
Acorda Reports Q3 2021 Financial Results, Additions to Leadership Team
09 Nov 2021 //
BUSINESSWIRE
Acorda offloads manufacturing operations to Catalent for $70M
14 Jan 2021 //
ENDPTS
EMA: Thumbs up for 11, down for 2 new medicines
25 Jul 2020 //
RAPS
SMC accepts four medicines for NHS use
14 Apr 2020 //
PHARMATIMES
Slow Inbrija launch forces Acorda to slash $800M sales hopes
14 Feb 2020 //
FIERCE PHARMA
Fampyra recommended in Wales after positive results in MS
21 Dec 2019 //
PHARMA TIMES
Micro Labs Generic Dalfampridine Receives Approval in US
12 Mar 2019 //
FDA
Micro Lab`s Generic Dalfampridine Receives Tentative Approval in US
02 Jan 2019 //
FDA
SMC endorses EUSA Pharma’s Qarziba
13 Nov 2018 //
PHARMA TIMES
West-Ward Pharms` Generic Dalfampridine Receives Approval in US
26 Oct 2018 //
FDA
Mylan Launches Authorized Generic of Ampyra® Tablets
21 Sep 2018 //
PR NEWSWIRE
Micro Labs` Generic Dalfampridine Receives Tentative Approval in US
03 Aug 2018 //
FDA
Acorda loses bid for U.S. court order halting generic Ampyra sales
26 Jul 2018 //
REUTERS
Accord Healthcare`s Generic Dalfampridine Receives Approval in the US
21 Jul 2018 //
FDA
CEO: Win or lose on Ampyra, Acorda`s reps are safe with Inbrija
06 Jun 2018 //
FIERCE PHARMA
Acorda Asks Fed. Circ. To Undo Nix Of Ampyra Drug Patents
11 Aug 2017 //
LAW360
Allergan Again Pressures FDA On Restasis Generics
11 Aug 2017 //
LAW360
Ampyra® (Dalfampridine): Acorda Therapeutics, Inc. V. Micro Labs
24 May 2017 //
PATENT LITIGATION
Full green light for Biogen’s MS drug Fampyra
24 May 2017 //
PHARMA TIMES
Under threat of early Ampyra knockoffs, Acorda plans to chop 100 jobs
05 Apr 2017 //
FIERCE PHARMA
Ampyra, Patents, And The Perils Of Letting PTAB Get Your Hopes Up
04 Apr 2017 //
PHARMAMEDTECHBI
Court nixes Acorda patents, teeing up Ampyra generics and potential cost cuts
03 Apr 2017 //
FIERCE PHARMA
Actavis`s Generic Dalfampridine Receives Approval In US
23 Jan 2017 //
FDA
Aurobindo`s Generic Dalfampridine Receives Approval In US
23 Jan 2017 //
FDA
Investors Upset as Acorda Abandons Development of Another Drug After PhII Flop
22 Nov 2016 //
BIOSPACE
SMC Endorses Use of Five Meds on NHS Scotland
08 Nov 2016 //
PHARMATIMES
Sorry, Celgene, patent board says. Bass can challenge your IP, and profit, too
29 Sep 2015 //
FIERCE PHARMA
Undeterred by PTO setbacks, Bass slaps new challenges on Acorda patents
04 Sep 2015 //
FIERCE PHARMA
Patent challenger Bass shrugs off Celgene`s attack on his short-selling motives
12 Aug 2015 //
FIERCE PHARMA
Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.
02 May 2015 //
FIERCE PHARMA MFG
Innovate or Else: Kyle Bass Strikes Again and Challenges Shire Patents
02 Apr 2015 //
PHARMALOT
